Allink Biotherapeutics is thrilled to announce a significant funding milestone as it raises $42 million to further advance its pioneering research in the field of dietary-related metabolic diseases. Founded on years of collaborative research from the University of Copenhagen, Antag Therapeutics has emerged as a frontrunner in developing innovative therapies, focusing on naturally occurring therapeutic peptides identified by esteemed professors Mette M. Rosenkilde and Jens J. Holst. This substantial injection of capital will not only accelerate the ongoing clinical studies but also support the development of novel treatment options aimed at combatting the rising prevalence of obesity and related metabolic disorders. As our understanding of therapeutic peptides deepens, Antag Therapeutics is poised to translate this knowledge into effective interventions that can significantly improve the health outcomes for millions of individuals grappling with metabolic diseases. The funds will be allocated towards expanding clinical trials, optimizing peptide formulations, and enhancing manufacturing capabilities. By leveraging this investment, Antag Therapeutics aims to bring groundbreaking solutions to market, ultimately reshaping the landscape of metabolic disease treatment and providing hope for patients in need. We are excited about the future and remain committed to our mission of transforming scientific breakthroughs into real-world applications that can improve lives globally. This funding round is a testament to the relentless dedication of our research teams and the confidence of our investors in our vision for a healthier future.
Innovative Biotech Startup Antag Therapeutics Secures $42 Million in Series A Funding for Groundbreaking Research on Dietary-Related Metabolic Diseases
Recently funded · $42.0M Series aBiotechnology
Get the full Allink Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
